ReviewAnnals of medicine and surgery (2012)2026
Borderline resectable pancreatic ductal adenocarcinoma: a narrative review.
Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is a well-recognized entity with specific characteristics. Previously considered inoperable, these tumors are now increasingly resectable due to advances in neoadjuvant chemotherapy. This review synthesizes current knowledge on diagnostic, therapeutic, and management approaches for pancreatic ductal adenocarcinoma, especially for BR disease. It covers the definition, criteria, and surgical management, along with various clinical challenges in the diagnosis of borderline disease. Neoadjuvant therapy is the treatment of choice before surgery, but there are still limited data on the selection of optimal therapy and on the early identification of non-responders. Multidetector computed tomography, along with CA19-9 and positron emission tomography, are being used to evaluate resectability after neoadjuvant therapy. Pancreatic resection for PDAC is one of the most complex procedures in abdominal surgery due to the technical and oncological challenges associated with its aggressive growth. Despite these options, management remains challenging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.